<DOC>
	<DOCNO>NCT01332435</DOCNO>
	<brief_summary>This retrospective study aim assess economic impact early initiation 5-alpha-reductase inhibitor ( 5ARI ) therapy patient enlarge prostate ( EP ) receive 5ARI alpha-blocker ( AB ) combination therapy . Both Integrated Health Care Information Solutions PharMetrics databases utilized study ( 2000-2007 ) .</brief_summary>
	<brief_title>Dutasteride Enlarged Prostate Economic Assessment : A Retrospective Database Pooled Analysis Early 5-alpha Reductase Inhibitor Use</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>5-alpha Reductase Inhibitors</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Male patient age 50 year old medical claim EP prescription claim 5ARI AB ( provide within 180 day index date ) continuously eligible 6 month prior least 12 month index prescription date . diagnosis prostate bladder cancer prostaterelated surgical procedure within 5 month index date prescription claim finasteride indicative male pattern baldness 5ARI therapy initiate prior initiate AB therapy</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Enlarged prostate , 5-alpha-reductase inhibitor , alpha-blocker , early , cost</keyword>
</DOC>